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Abstract: 
For pharmaceutical industry, the preformulation screening of the compatibility of drug and 
polymeric excipients can often be time-consuming due to the use of trial-and-error approaches. 
This is also the case for selecting highly effective polymeric excipients for forming molecular 
dispersions in order to improve the dissolution and subsequent bioavailability of a poorly 
soluble drug. Previously we developed a new thermal imaging-based rapid screening method, 
thermal analysis by structure characterization (TASC), which can rapidly detect the melting 
point depression of a crystalline drug in the presence of a polymeric material. In this study, we 
used melting point depression as an indicator of a drug solubility in a polymer and further 
explored the potential of using TASC method to rapidly screen and identify polymers in which 
a drug is likely to have a high solubility. Here we used a data bank of 5 model drugs and 10 
different pharmaceutical grade polymers to valid the screening potential of TASC. The data 
indicated that TASC could provide a significant improvement to the screening speed and reduce 
the materials used without compromising the sensitivity of detection. It should be highlighted 
that the current method is a screening method rather than a method that provides absolute 
measurement of the degree of solubility of a drug in a polymer. The results of this study 
confirmed that the TASC results of each drug-polymer pair could be used in data matrices to 
indicate the presence of significant interaction and solubility of the drug in the polymer. This 
forms the foundation for automating the screening process using artificial intelligence.  
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Abbreviations: 
TASC: thermal analysis by structure characterization 
ROI: region of interest 
DSC: differential scanning calorimetry  
TBA: tolbutamide  
IMC: indomethacin  
FDN: felodipine  
FFB: fenofibrate  
IBP: ibuprofen  
PVPVA: Polyvinylpyrrolidone/vinyl acetate 
HPC: hydroxyl propyl cellulose  
HPMCAS: hydroxypropyl methyl cellulose acetyl succinate 
NaCMC: sodium carboxymethyl cellulose  
EU: Eudragit EPO 
PVP: polyvinylpyrrolidone  
HEC: hydroxyethyl cellulose  
PAA: polyacrylic acid  
PVA: polyvinyl alcohol  
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1. Introduction  
Polymers have been widely used in pharmaceutical solid dosage forms as functional excipients 
to create matrices in which the drug can be molecularly dispersed.1-3 Such solid dispersions 
have been widely studied for oral dosage forms and can significantly alter the release rate of 
the drug in comparison to the crystal form of the drug.4-6 When a molecular dispersion is 
formed, if the polymer is highly soluble in the gut fluid, the formation of the drug-polymer 
dispersion will enhance the dissolution of the drug that is molecularly dispersed in the polymer.7  
If the polymer is poorly soluble, the drug release will be retarded and can be used to control the 
release rate of the drug.8  In order to allow the drug to form a molecular dispersion with the 
polymer, the drug needs to be soluble in the polymer and form a kinetically stable 
supersaturated solution in the polymer, or to form a thermodynamically stable solution in which 
the drug is available at therapeutically useful levels.9  In much of the pharmaceutical literature, 
these conditions have been loosely termed ‘drug-polymer miscibility’ and often used 
interchangeably with ‘drug-polymer solubility’.10,11 Therefore, it is highly useful to 
pharmaceutical industry when developing such drug-polymer based products to firstly know 
whether the drug is soluble in the polymer and can form stable miscible products.  
 
In the true thermodynamic terms, formation of true solutions requires a negative change in the 
free energy of mixing, ∆Gmix. Most of the pharmaceutical polymer and low molecular weight 
drug combinations have limited solubility ranges. A range of theoretical and experimental 
methods has been reported for measuring this.10,12,13 Examples of such measurement include 
using the solubility parameter to estimate the favourable interaction of drug and polymer,14,15 
using melting point depression and the subsequent calculation based on the extended Flory-
Huggins theory to determine drug solubility in polymer,12,16,17 using thermal analysis such as 
differential scanning calorimetry (DSC) to measure the recrystallization and dissolution end 
point of a pre-prepared supersaturated solid dispersion.18,19 However the experimental 
procedures are highly time-consuming and all rely on theoretical models of uncertain accuracy 
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to predict miscibility and solubility.20 Here we report on the use of thermal analysis by structure 
characterization (TASC) to rapidly obtain data that are indicative of drug-polymer solubility. 
TASC is a microscopy-based method and is performed by analyzing the feature changes of the 
crystalline drug particle as it is heated in a linear fashion and melted on a thin layer of the 
polymer of interest.21 The speed of the detection of the key measure of drug-polymer interaction 
(melting point depression) using TASC is 20-40 times faster than the conventional DSC method 
without loss of the sensitivity of detection.22 Each TASC run only required 1/1000th of the 
quantity of the material that is needed for a conventional DSC test.22 
 
 
Figure 1. Illustration of the working principle of TASC, the typical sample configuration used 
for TASC screening and the typical TASC data output.  
 
The working principle of the screening method has been described in detail previously.21 It is a 
conventional light microscope based method which detect changes in images automatically. It 
does this by comparing a sequence of images pixel by pixel. In brief, a series of images of the 
samples during thermal treatment (either being heating, cooling or isothermal) is taken and the 
TASC algorithm quantifies the changes of features in successive micrographs of samples. Such 
quantification is performed by subtracting the numerical value of each pixel of the selected 
region of interest (ROI) from its precursor and the sum of the moduli of differences is calculated 
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(as illustrated in Figure 1). The normalisation of the TASC value within one thermal scan is 
performed by taking the ratio of each image to the final set of images in which there is no 
sequential change. In practise, for samples melted on a polymer film surface, the flow of liquid 
may take some time to cease in which case the stable state is reached at a temperature higher 
than shown on the graphs. Hence the normalised TASC values as plotted may not reach unity. 
 
Our previous data demonstrated the ability to screen a single drug against a range of 
pharmaceutical grades of polymers.22 Using this as the conceptual foundation, the potential for 
automating the screening method is being explored in this study. In order to validate the 
automation potential, it is vitally important to demonstrate that the behavior observed in a single 
drug case can be generalized to a wide range of different drugs with a wide range of 
physicochemical properties. For this purpose, five drugs were tested against ten polymers. 
Using conventional methods screening fifty drug/polymer combinations would have required 
an impractical amount of time, but the speed of the TASC method allows such large-scale 
measurements. Such a rapid throughput indicates the potential for automation as the next stage 
of the development of the TASC screening method.  
 
It is important to be clear what TASC does and does not measure. TASC is a screening method 
rather than a method that provides absolute measurement of the degree of solubility of a drug 
in a polymer. If the drug crystal is able to dissolve in the polymer, then a reduced melting point 
of the drug crystal will be detected by TASC. However this observation does not necessarily 
carry any information about the concentration range over which the system is soluble or the 
temperature range of solubility. If no depression of melting point is detected, this is a clear 
indication of the lack of solubility. The TASC method, when it is limited to simple melting 
point determination, must therefore be regarded as a screening method which can eliminate 
combinations of drug and polymer where thermodynamically stable solutions cannot be 
formed. This in itself can be valuable as the method requires very small amounts of material 
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and is very rapid. Melting point depression is a single point determination; in this paper we 
extend this to the use of the whole TASC curve by employing principal component analysis 
(PCA). This approach allows the construction of a database which will enable the behavior of 
new drug/polymer combinations to be compared directly with the behavior of a wide range of 
other combinations. Such a database will be a requirement if the method is to be developed as 
high throughput automated system. 
 
2. Results and Discussion 
Figure 2 shows an example of the sequence of feature changes observed in the melting of a 
crystalline drug particle, IMC, and their corresponding normalised TASC value on a TASC 
plot. The point where the curve for the pure drug deviates from the baseline is well defined and 
may be used to measure the onset of the melting point of the drug.21,22 As seen in Figure 2, the 
extrapolated melting onset measured by TASC is 160.5 ± 1.4 °C, which is very close to that 
measured by DSC (DSC melting onset = 159.2 ± 0.04 °C and DSC melting peak = 161.0 ± 0.3 
°C). The 2 °C deviation between the onset measured by TASC and DSC could be attributed to 
the difference on the method used to measure the melting of the drug particles. In a DSC pan, 
the melting signal is an average of the bulk powder in the pan through a highly thermal-
conductive metal pan surface; whereas in TASC, the signal is the feature change of individual 
drug particles.  
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Figure 2 A typical TASC plot of the melting of a crystalline drug particle (IMC) with the 
microscopic images at different stages of the heating, and the comparison with the melting 
onset temperature with the DSC (insert). The heating rate was 20 ˚C/min in both cases.  
 
When the glass substrate is coated with a thin film of the polymer of interest, same principle of 
measurement applies. An example TASC plot for a crystalline drug particle heated on a variety 
of polymer surfaces is shown in Figure 3 (the complete set of plots for all 5 drugs are shown in 
the Supplementary Information). In comparison to the IMC drug particle melting on un-coated 
glass substrate, the behaviour of the crystals on polymer surfaces is somewhat different: the 
curves are more complex and deviate from the baseline at a temperature below the pure drug 
melting point. This behaviour is typical of a melting point depression effect due to the 
interaction of the drug and the polymer. As shown in Figure 3, the degree of depression of the 
melting of the crystalline drug particle changes depending on the type of the polymer 
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underneath. In this case, the data show that Eudragit EPO induced highest level of depression 
of the IMC melting and PVA (with high degree of hydrolysis of 88%) caused least depression. 
This indicates that Eudragit EPO is most soluble with IMC and PVA being the least soluble 
when comparing the set of polymers’ capability of mixing with IMC. These results agree 
extremely well with the data reported in the literature and measured by other methods.23-25 
Therefore such difference can be used as the underlying principle for using TASC to rank the 
usefulness of the polymeric excipients for solid dispersion formulation development.  
 
Figure 3 TASC plots for indomethacin (IMC) as pure drug and on PVA, PVP K29/32, PVPVA, 
Soluplus, and Eudragit EPO (n=5) 
 
For studying individual cases, the depressed onset of melting temperature measured by TASC 
may be measured by a number of methods.22 However as shown in Figure 4, the TASC curves 
can become less easy to analyse by any of the methods used previously and certain amount of 
subjectivity can be introduced. In addition using a single onset data point, as demonstrated in 
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Figure 2, does not make use of the whole data set and, for the purposes of a high throughput 
method, does not lend itself readily to automation.  
 
Figure 4. TASC plots for tolbutamide (TBA) as pure drug and on HEC, HPC, HPMCAS, 
NaCMC, PVA, PVPVA, Soluplus, and Eudragit EPO (n=5) 
 
Classification of the TASC curves by principal component analysis (PCA) is rapid. It allows 
the use of the whole TASC data set of each run which builds the potential foundation for 
automation. In addition, each data set may be added to an existing set, so that new 
measurements may be classified by comparison with existing data on drug/polymer 
interactions. The first two components (P1 and P2) separate the data well and the P2 correlates 
well with the estimated reduced melting point. P1 accounts for 91.9% of the variance and P2 
for 5.8% (the loading plot of the P1 and P2 can be found in Supplementary Information). As is 
often the case in PCA component 1 responds to the whole shape of the curve. Component 2 has 
contributions that are evenly balanced around the zero of the reduced temperature, which 
corresponds to the melting point of the pure drug. Thus transition points or flatter regions near 
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to the pure melting point of a TASC curve tend to cancel out and reduce the value of P2. At 
lower temperatures the higher intensities cause more positive the values of P2 tending to make 
lower melting point curves contribute to the positive intensity of P2. However it is important 
to point out that all sections of the curve contributes significantly to P2 and that as data bases 
are further developed the contributions from all of the curves to P2 may become useful in the 
classification of drug-polymer interactions. 
 
Using the combined data, it is possible to put any drug-polymer combination on a universal 
scale. Thus for any particular combination, it is possible to compare with a range of drug-
polymer interactions. A plot of the first two principal components (P1, P2) of the five model 
drug and 10 model polymer combinations is shown in Figure 5. Usually in such an analysis it 
would be expected that PCA would separate the data into clusters rather than the spread of 
values observed here. However this spread merely reflects the range of drug-polymer 
solubility/interactions that exist.  
 
Using IMC as the example, the P2 component separates clearly the highly soluble pair of IMC-
Eudragit EPO from the poorly soluble pair of IMC-PVA, which agrees well with the existing 
literature data obtained by other solubility measurement methods.23-25 The TASC data of the 
IMC melted on the other polymer are scattered in between the P2 scale of Eudragit EPO and 
PVA, possibly indicating different degrees of solubility. The TASC data of the pure drug 
crystals on uncoated glass slides (with no melting point depression) are all clustered at the left-
hand side of the PCA plot. Therefore it is valid to suggest that the drug-polymer pairs clustered 
in the left-hand side of the PCA plot are poorly soluble and the higher P2 values on the scale 
the pairs have the higher likelihood of being soluble. However, as discussed below, some 
degree of caution is necessary 
12 
 
 
Figure 5 A plot of the first and second principal components, P1 versus P2, of the PCA analysis 
of the TASC full curve data of five drugs with ten polymers. 
 
In order to compare P2 with the onset of melting, a parameter, ∆T, has been defined as the 
difference between the onset temperature of the depressed melting (measured by TASC when 
the drug crystals were placed on top of the polymer coated glass substrate) and the melting of 
the pure drug (measured without the presence of polymer). A plot of ∆T versus P2 is shown in 
Figure 6. P2 is negative for all systems having a value of ∆T between 0 and -6 °C. Melting 
point depressions (the absolute value of ∆T) greater than 6 °C lead to a positive value of P2. 
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Figure 6 Plot of the values of the second principal component (P2) versus the depression of 
onset of the melting temperature (∆T). 
 
In the TASC experiments described here the amount of drug available at the point of contact 
with the polymer film underneath is very limited. Therefore the ratio of drug to polymer 
detected in each TASC measurement is very low. If the drug was soluble in the polymer at 
room temperature, then from the thermodynamic point of view, merely placing a crystal of the 
drug on the polymer would result in the spontaneous formation of a solution. This happens with 
sodium chloride and water for example. In our case the dynamics of the situation are such that 
the spontaneous behaviour is not possible. So as the system is heated two things happen, the 
polymer becomes more mobile (increased molecular mobility with increasing the temperature 
by heating to the temperature below the Tg of the polymer, and the transformation to its rubbery 
state when it is heated to above the Tg of the polymer) and more able to form solutions and, in 
general, increasing temperature results in increasing solubility. The drug crystal is absorbing 
heat energy and therefore intermolecular interactions are being weakened. At some point during 
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the heating, the increasing solvent properties of the polymer and increasing weakening of the 
intermolecular bonds are sufficient that the energy derived from solution formation is enough 
to cause the drug to dissolve with the consequent observation of crystal melting. The lower the 
melting point of the drug the less energy will be required to overcome the internal bonding of 
the crystal.  
 
The depressed melting (∆T) observed in our experiments is not easily compared to the 
depressed melting observed in calorimetric experiments due to the difference in the working 
principle of these two analytical methods. In the calorimetric method for measuring melting 
point depression in the presence of polymer, an intimate mixture of the drug and polymer is 
made and conditions as near possible to thermodynamic equilibrium are sought.20 This 
necessarily involves a very slow heating regime of typically 0.5 or 1 °C/min.10,13 The 
experiment measures the solubility of the drug in the polymer by reaching the temperature 
where the drug:polymer ratio is such that a saturated solution of drug may be formed. At this 
temperature the drug melts and a solution is formed. This is observed calorimetrically as the 
uptake of the heat of fusion of the drug and the temperature of melting is used to calculate the 
reduction of melting point. Therefore the variations of the ∆T measured by TASC may not 
carry an implication about magnitude of the drug solubility, except in the case where ∆T is 
close to zero, as in this case no solution takes place. Generally, ∆T will depend on the intrinsic 
intermolecular bonding in the drug crystal and both the dynamics and solvating power of the 
polymer. For this reason the ∆T value may not be a very good indicator of actual solubility, and 
the use of PCA to classify curves as whole may be a better way to build a database in which 
comparisons are made between curves of test materials and the known behaviour of existing 
combinations that are already stored in the database. 
 
Our methodology therefore for each drug sorts the polymers into a comparative spectrum of 
being soluble, partially soluble and insoluble with the drug, but does not measure the absolute 
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degree of solubility of the drug in the polymer. In order to explore the predictive capacity of 
the TASC method, literature search on the physical stability of this study’s model drug-polymer 
combinations reported by other studies was carried out (the systems and references can be found 
in the Supplementary Information). It became clear that in the literature the methods of 
preparation of drug-polymer dispersions and storage conditions were highly variable. In this 
study, experiments were carried out with the sample of drug-polymer dispersions being 
prepared by spin-coating and being stored at a unified storage condition, ambient 
temperature/75% RH. The conditions are commonly used for accelerated testing of storage 
stability. It is therefore useful to examine the predictive capacity and correlation of the TASC 
measurement to real storage stability. The analysis was performed based on the assumption that 
drug-polymer combinations with good solubility would have good storage stability. The system 
was classified as stable if there was no drug crystallization after one month of storage. Two 
drug loadings, 30% and 60% (w/w), were used. Table 1 compares the stabilities with the second 
principal component (P2) of the PCA analysis. 
 
Table 1 Summary of the TASC predicted storage stability and 1-month real-time storage 
stability data of 14 pairs of drug-polymer dispersions with 30% and 60% (w/w) drug loading.  
Drug-polymer 
dispersions 
P2 value 
from PCA 
TASC 
predicted  
stability 
1-month real-time 
stability (30% drug 
loading) 
1-month real-time 
stability (60% drug 
loading) 
FFB-PVPVA -0.22 no no no 
IBP-PAA -0.21 no no no 
IMC-PAA -0.18 no yes no 
TBA-PAA -0.17 no no no 
FFB-HPC -0.17 no no no 
IMC-HPC -0.13 no yes yes 
FDN-PAA -0.12 no no no 
TBA-HPMCAS -0.01 no no no 
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FFB-Eudragit 
EPO 
0.03 yes yes no 
IBP-PVP 
K29/32 
0.17 yes no no 
FDN-Soluplus 0.21 yes yes yes 
IBP-Eudragit 
EPO 
0.32 yes yes no 
TBA-Eudragit 
EPO 
0.51 yes yes yes 
IMC-Eudragit 
EPO 
0.66 yes yes yes 
 
 
Figure 7.  Distribution of the agreement between TASC prediction (using P2 value of the 
PCA analysis of the TASC data) and the real-time storage stability data using ambient 
temperature/75% RH.  
 
It is clear from the data in Table 1 and Figure 7 that ∆T and P2 (generated from TASC data) 
correlate well in prediction of storage stability, but it is notable that the two IMC samples show 
anomalous behaviour; being stable when the TASC results suggest instability. This may be the 
formation of stable supersaturated solutions.26 In some cases, the 60% system is not stable but 
the 30% system is. This agrees well with the general trend of a lower drug-loaded system 
containing less amorphous drug and significantly more amount of the polymer being 
characterized by a greater physical stability than that described in the literature. For some drug-
polymer combinations, this could be also caused by the drug loading being over the solubility 
limit for the system which is not predicted by the TASC method. This highlights the fact that 
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TASC is an indicator of solubility but does not make quantitative predictions of solubility limits 
not the effects of varying humidity.  
 
A glaring anomaly is the IBP-PVP K29/32 disperion where no stability is observed but the 
reduction in melting point is very clear. However the polymer PVP K29/32 is highly 
hygroscopic and absorbs water very readily.  Under these storage conditions it can absorb a 
considerable amount of water (20% at 25 °C) which can disrupt drug polymer hydrogen 
bonding.27 It should be born in mind that TASC measurements and predictions do not take 
account of the effects of moisture. Therefore the instability of the model samples may be 
attributed to the effect of humidity instead lack of drug-polymer solubility in the dry state.  
 
In the case of IMC-HPC, the melting of IMC is 44 °C below the Tg of HPC. This may help with 
kinetic stabilisation. In addition, crystallization requires the presence of the appropriate nuclei. 
If these are absent, crystallization will not take place unless supersaturation is so high that 
homo-nucleation occurs. Both of these might lead to kinetic stability as opposed to 
thermodynamic stability. These results indicate that using thermodynamic measurement for 
solubility detection is more reliable than kinetic approaches. The kinetically stabilised systems 
are inherently unstable and slight changes in storage conditions may result in crystallization.  
 
A more extensive study on the physical stability of drug-polymer dispersions (prepared by film 
formation) is reported by Fridgeirsdottir and co-workers, in which 10 different drugs at 10% 
loading with 3 different polymers (HPMCAS, PVPVA and Soluplus) were prepared and stored 
under 75% RH/40 °C.28 In all cases, the storage resulted in the drug recrystallization within a 
year, with one exception.28 FFB-PVPVA and FDN-Soluplus at 30 and 60% loadings in our 
work (stored at ambient temperature/75% RH) can be compared with the same samples at 10% 
loadings (stored at 40 °C/75% RH) reported by Fridgeirsdottir and co-workers,28 as shown in 
Table 2. We find that for FFB-PVPVA, drug crystals were formed after 1 month but for FDN-
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Soluplus we did not observe any drug crystal formation (which may related to the higher storage 
temperature used in reference 28). It might be expected that with very high drug loading of the 
FDN-Soluplus dispersion, drug crystallisation would have occurred in one month if it occurred 
for 10% drug loading in 24 weeks. This suggests that in a system that is intrinsically unstable 
the effect of preparation history might be critical. It seems clear that the prediction of storage 
stability under extreme storage conditions is not easy and that sample preparation history may 
play an important role so that simple comparisons are not straightforward.20 
 
Table 2. Comparison of the predicted storage stability using P2 values of the PCA analysis of 
TASC results of this study and the experimental storage stability reported in Ref 28.  
Drug Polymer P2 value from PCA Stability * 
FDN HPMCAS 0.02 1 week (a) 
PVPVA 0.22 16 weeks (a) 
Soluplus 0.47 24 weeks (a) 
FFB HPMCAS -0.21 6 weeks (b) 
PVPVA -0.22 Less than 4 weeks (b) 
Soluplus -0.16  6 months (b) 
Stability* here refers to the storage stability using drug recrystallization as the key indicator 
under the storage condition of 40 °C/75% RH.  
a: data given as numerical values in Ref 28 
b: data estimated from Figures in Ref 28 
 
An interesting sub-group of drug-polymer systems are listed in Table 3. For these drug-polymer 
combinations, the onset of the drug melting temperature is well below the Tg of the polymer. It 
would be expected that in a polymeric system below the glass transition temperature polymer 
dynamics would be so slow that any interaction with the drug crystal would be precluded. 
However the interaction is not with the bulk polymer but at the polymer surface where the 
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interface with air allows a greater free volume than in the bulk. It must be concluded therefore 
that the mobility at the interface is much greater than in the bulk allowing crystal/polymer 
interactions to take place. 
Table 3 Drug-polymer combinations in which the onset of drug melting temperature is below 
the Tg of the polymer 
System Tm (°C)a Tg (°C)b Depression (∆T) (°C)c Tg-Tm (°C) 
TBA-HEC 121 130 -7 9 
IBP-Soluplus 61 72.2 -15 11.2 
IMC-PVP K29/32 136.5 160.3 -24.5 23.8 
TBA-PVP K29/32 105 160.3 -23 55.3 
FDN-HPC 117.4 205 -27.6 87.6 
TBA-HPC 109 205 -19 96 
IBP-PVP K29/32 61 160.3 -15 99.3 
a: onset of drug melting measured by DSC 
b: Tg of polymer measured by DSC 
c: Depression of the onset of drug melting in the presence of polymer measured by TASC 
 
3. Conclusion 
A large number of TASC data sets of the measurements of the crystalline drug particle melting 
on top of the thin films of a wide range of typically used polymers in solid dispersion 
formulations were generated. With the intension of exploring the automation potential of TASC 
method for rapid formulation screening, the full TASC plots of all drug-polymer pairs were 
analysed using PCA instead of comparing the depressed onset of melting as a single point 
measurement. This demonstrated the clear potential of TASC to be developed into an automatic 
rapid formulation screening tool for drug-polymer based formulations to allow the formulators 
to rank the miscibility between the drug of interest and a list of potential polymeric excipients. 
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It should be highlighted that the current method is a screening method rather than a method that 
provides absolute measurement of the degree of solubility of a drug in a polymer. 
 
It is not simply the rapidity of the heating rate of the TASC measurement that facilitates high 
throughput there is also the option of using arrays of microscopes or, more likely, borescopes. 
Off-the-shelf devices are readily available at low cost. Their tube-like shape is with a 6mm 
diameter means an array of 10x10 could easily be achieved. Creating a hot stage of 60x60 mm 
is also straightforward. This would increase throughput by x100. Within each field of view 10 
crystals could be automatically identified and located. This means carrying out 1000 
experiments simultaneously is far from impossible. The instrument itself could be inexpensive 
with a small footprint on a laboratory bench. The data analysis could also be automated so the 
user could see averaged plots and PC graphs within minutes. The hot stage could be designed 
that each row of 10 borescopes could use a different heating rate thus enabling the role of 
kinetics to be evaluated. 
4. Experimental Section 
Materials 
The five model drugs used in this study are tolbutamide (with >98% purity) (TBA) and 
indomethacin (with 98.5% purity) (IMC) were purchased from Sigma-Aldrich (St. Louis, US), 
felodipine (with ≥99% purity) (FDN) was purchased from Molekula (Dorest, UK), fenofibrate 
(with ≥99% purity) (FFB) and ibuprofen (with ≥98% purity) (IBP) were kindly donated by 
Merck Serono (Darmstadt, Germany) and BASF (Ludwigshafen, Germany), respectively. The 
10 polymers used in this study are: polyvinyl pyrrolidone vinyl acetate (PVPVA) Plasdone™ 
S630 (with an average molecular weight of 47,000 g/mol), hydroxyl propyl cellulose (HPC) 
Klucel™ EF PHARM (with an average molecular weight of 80,000 g/mol), hydroxypropyl 
methyl cellulose acetyl succinate (HPMCAS MG) AquaSolve™ (with an average molecular 
weight of 103,200 g/mol), sodium carboxy methyl cellulose (Na CMC) Aqualon™ CMC 7L2P 
(with an average molecular weight of 49,000 g/mol), polyvinyl pyrrolidone (PVP) Plasdone™ 
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K29-32 (with an average molecular weight of 58,000 g/mol), hydroxyethyl cellulose (HEC) 
Natrosol™ 250 L PHARM (with an average molecular weight of 90,000 g/mol) were kindly 
donated from Ashland Industries Europe GmbH (Schaffhausen, Switzerland). Polyacrylic acid 
(PAA) (with an average molecular weight of 450,000 g/mol) was purchased from Sigma-
Aldrich (St. Louis, US). Poly (butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-
comethyl methacrylate) (Eudragit® EPO) (with an average molecular weight of 47,000 g/mol) 
was kindly donated by Evonik Industries (Darmstadt, Germany). Polyvinyl alcohol (PVA) 88% 
(with an average molecular weight of 44.053 g/mol) hydrolysed was purchased from Acros 
Organics (New Jersey, USA). Polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol 
graft copolymer (Soluplus®) (with an average molecular weight in the range of 90,000-140,000 
g/mol) was kindly donated from BASF (Ludwigshafen, Germany). NaCl (with ≥ 99.0 % purity) 
was purchased from Thermo Fisher Scientific (Geel, Belgium).  
 
Preparation of the polymer coated substrates using spin coating 
Spin coated thin films of different polymers on glass substrates were prepared using Spincoat 
G3P-8 (Specialty Coating Systems, Indianapolis, US). Solutions of the various polymers were 
prepared using different solvents and concentrations as shown in Table S1 in the supplementary 
information. In all cases, 2-5 drops of the prepared solutions were transferred to the top of a 
glass coverslip (Academy cover slip 18X18mm 01.6-0.19mm thick, Smith Scientific Limited, 
Ken, UK) followed by continuous spinning using 2000 rpm for 120 seconds to evaporate the 
solvent and formation of the polymeric thin films. The complete solvent removal at the end of 
spin coating process was confirmed by no measurable weight loss when the samples were tested 
using thermal gravimetric analysis (TGA) with heating to 105 °C and maintaining isothermal 
for 15 minutes. In our previous study, it was confirmed that the thickness of the polymer films 
does not significantly affect the TASC results.22   
 
Preparation of drug-polymer films and stability testing 
22 
 
In order to evaluate the stability of the five model drugs in the different polymers, spin coated 
solid dispersions of each drug in three different polymers (which are predicted by TASC to 
have high, intermediate and low drug-polymer solubility) were prepared. The solid dispersions 
films with drug: polymer concentration ratios of 0:10 (w/w) to 10:0 (with 10% w/w increments) 
were prepared by spin coating (using the same spin coating conditions described in the section 
above). The films were stored under the conditions of 75% RH/ambient temperature 
(21.7±1.8 °C). To rapidly screen the stability of the aged films, the recrystallization of drug in 
the aged films was used as an indicator of the instability of the dispersion. The spin-coated solid 
dispersion samples were examined using a Leica DM LS2 polarized light microscope (Leica 
Microsystems Wetzlar GmbH, Wetzlar, Germany) that was connected to JVC digital colour 
video camera and a PC. The aged samples were examined thoroughly under the polarized light 
microscope after 1 week, 2 weeks and 1 month of storage. 
 
TASC Analysis  
TASC analysis was performed using TASC system composed of a Linkam MDSG600 heat-
cool automated temperature controlling stage attached to a Linkam imaging station equipped 
with reflective LED light source and a x10 magnification lens (Linkam Scientific Instruments 
Ltd, Surry, UK). Liquid nitrogen was purged into the stage for controlled cooling of the stage 
during the cooling cycles. The drug particles used for TASC analysis were selected within a 
size range of (90-100 µm) using a sieving method. Particles passing through a 100-µm sieve 
and retained by 90-µm sieve were collected and used for TASC analysis. TASC analysis was 
performed on the drug particles on the different polymeric films using a heating rate of 20 
ºC/min.  
 
For all TASC experiments, stacks of images of the sample were collected at a rate of 1 frame/ºC 
(with a starting temperature of 30 °C) using a black background to restrict the analysis to the 
crystalline drug particles and reduce the noise to signal ratio. These acquired images were 
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analyzed using TASC software and the changes in the appearance of drug particles were 
converted into normalized TASC curves. For each drug-polymer combination, the TASC 
analysis was performed on at least five different drug particles for each set of data using 
relatively large regions of interest (ROIs). The optimizations criteria of the selection of ROIs 
are the reproducibility of the data and the minimization of the variations in dimensionality 
between the particles. Such optimization is explained in detail in our previous work.22 The 
TASC plots presented in all data Figures are the average values taken from the TASC results 
of 5 different particles.  
 
Differential Scanning Calorimetry (DSC)  
A Q-2000 MTDSC (TA Instruments, Newcastle, USA) equipped with a RC 90 cooling unit 
was used to characterize the melting and the glass transitions of all raw materials. The 
instrument was calibrated prior to the sample characterization. At least three repeats of 2-3 mg 
of each sample were analyzed using standard aluminum TA crimped pans (TA Instruments, 
Newcastle, USA). Universal Analysis software was used to analyze the collected DSC results. 
A heating rate of 20 ºC/min was used in all cases in order to be consistent with the TASC 
measurements. All DSC results were highly reproducible with standard deviations of all data 
point being less than 0.025% for the melting onset measurements and less than 0.18% for the 
melting peak temperature measurements.  
 
Principle component analysis (PCA) 
PCA was carried out using the IBM SPSS 25 software package. Application of PCA to the 
whole data set of TASC profiles of drug and polymers encountered the problem that the 
temperature range of each set of experiments was determined by the pure drug melting point. 
The range must run from the starting temperature (30 °C) to the drug melting point. In the 
experiments described here, the range of melting points is from 76 °C (IBP) to 161 °C (IMC). 
Since sampling is made at regular temperature intervals this means that the number of data 
24 
 
points for each set of drug measurements is different. Scaling the sampling interval to ensure 
the same number of data points on for each drug would change the density of points and, for 
low melting drugs, oversample the curves. The approach taken was to estimate the melting 
point of the pure drug by taking the maximum of the first derivative of the TASC curve, then 
subtracting this value from all the measured temperatures. Thus the reduced temperature, 
termed as TR, is defined as TR= TS-TM. Where TS is the sampling temperature and TM is the 
measured melting point of the pure drug by TASC.  In this way all the curves are set about a 
common temperature zero. In order to get the same number of points on each curve only data 
in the range of TR= +17 to -46 °C is used. PCA is applied using this normalised data. 
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Supporting Information  
• Table S1: Polymeric solutions concentrations, solvent systems and thickness for the 
prepared spin coated films for TASC analysis 
• Figure S1: Pure indomethacin (IMC) on glass slides without polymer coating and the 
glass slides coated with 10 different polymers. All curves are taken as the average of 5 
TASC measurements on 5 different drug particles. 
• Figure S2: Pure tolbutamide (TBA) on glass slides without polymer coating and the 
glass slides coated with 10 different polymers. All curves are taken as the average of 5 
TASC measurements on 5 different drug particles. 
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• Figure S3: Pure felodipine (FDN) on glass slides without polymer coating and the glass 
slides coated with 10 different polymers. All curves are taken as the average of 5 TASC 
measurements on 5 different drug particles. 
• Figure S4: Pure fenofibrate (FFB) on glass slides without polymer coating and the glass 
slides coated with 10 different polymers. All curves are taken as the average of 5 TASC 
measurements on 5 different drug particles. 
• Figure S5: Pure ibuprofen (IBP) on glass slides without polymer coating and the glass 
slides coated with 10 different polymers. All curves are taken as the average of 5 TASC 
measurements on 5 different drug particles. 
• Figure S6 DSC thermograms showing the melting point depression of felodipine by 
Soluplus and PVPVA using 9:1 drug to polymer PM and 5 °C/min. 
• Figure S7 The loading plot of the PC1 and PC2 of the PCA analysis 
• Table S2 Literature search results of the relevant solubility and storage stability 
information of indomethacin-polymer pairs. 
• Table S3 Literature search results of the relevant solubility and storage stability 
information of ibuprofen-polymer pairs. 
• Table S4 Literature search results of the relevant solubility and storage stability 
information of tolbutamide-polymer pairs. 
• Table S5 Literature search results of the relevant solubility and storage stability 
information of felodipine-polymer pairs. 
• Table S6 Literature search results of the relevant solubility and storage stability 
information of fenofibrate-polymer pairs. 
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